Shorter versus longer chemotherapy for stage II stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two lengths of an oral chemotherapy medicine (9 months vs 1 year) after surgery for stage II stomach cancer. It aims to see which schedule works better and is easier to complete, while checking safety for people without major health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 75.
- Your stomach cancer is confirmed as primary adenocarcinoma and is stage II based on pathology (exam of tissue).
- You already had surgery that fully removed the tumor (R0 resection) plus lymph node removal (D2 lymph node dissection).
- You do not have another active cancer and you have not had cancer other than this one.
- Your general health is good enough for chemotherapy (ECOG 0–1) and you’re expected to live more than 6 months.
- Your blood, liver, and kidney tests and heart tracing (ECG) are within acceptable ranges for chemotherapy (for example, enough white blood cells, platelets, and hemoglobin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment plan for stomach cancer that combines chemotherapy and a shorter course of radiation before surgery. The goal is to see if this approach is safe and effective.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
This trial compares two chemotherapy combinations given before surgery for stomach cancer that has not spread. The goal is to see which treatment works better and to shrink the tumor before removal.
This trial studies whether giving oxaliplatin plus S-1 (SOX) chemotherapy before stomach surgery works best when given for different cycle lengths. It may help shrink stage III gastric cancer before a standard D2 gastrectomy and improve outcomes.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial compares two chemotherapy combinations (oxaliplatin plus S-1 vs docetaxel plus S-1) for people with stage III stomach cancer who have had complete surgical removal of the tumor. The goal is to see which combination works better to prevent cancer from returning.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.